MFIM
CHRS icon

Mesirow Financial Investment Management’s Coherus Oncology CHRS Stock Holding History

Mesirow Financial Investment Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-31,986
Closed -$219K – 86
2023
Q1 		$219K Hold
31,986
– – 0.91% 62
2022
Q4 		$253K Hold
31,986
– – 1.06% 53
2022
Q3 		$307K Buy
+31,986
New +$324K 1.46% 30

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Mesirow Financial Investment Management's CHRS Position: Q2 2023 in Review

Mesirow Financial Investment Management sold out of Coherus Oncology (CHRS) in Q2 2023, closing a stake of 31,986 shares — an estimated $219K sold.

Mesirow Financial Investment Management first reported a position in CHRS in Q3 2022 and held it in 3 quarters. The position peaked at $307K in Q3 2022. 161 funds tracked by Wall St. Rank hold CHRS as of Q2 2023.

  • Mesirow Financial Investment Management reported no remaining Coherus Oncology position as of Q2 2023 after selling out during the quarter.
  • Mesirow Financial Investment Management sold 31,986 Coherus Oncology shares in Q2 2023, an estimated $219K.
  • Mesirow Financial Investment Management first reported a position in Coherus Oncology in Q3 2022 and held it in 3 quarters.
  • Mesirow Financial Investment Management's Coherus Oncology position peaked at $307K in Q3 2022.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2023.

Based on Mesirow Financial Investment Management's 13F filing for Q2 2023, filed 17 Jul 2023.